Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Prepaid Assets (2016 - 2025)

Coherus Oncology's Prepaid Assets history spans 13 years, with the latest figure at $6.2 million for Q4 2025.

  • For Q4 2025, Prepaid Assets fell 6.31% year-over-year to $6.2 million; the TTM value through Dec 2025 reached $6.2 million, down 6.31%, while the annual FY2025 figure was $6.2 million, 6.31% down from the prior year.
  • Prepaid Assets for Q4 2025 was $6.2 million at Coherus Oncology, down from $8.7 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $21.9 million in Q3 2022 and bottomed at $6.2 million in Q4 2025.
  • The 5-year median for Prepaid Assets is $13.8 million (2023), against an average of $13.3 million.
  • The largest YoY upside for Prepaid Assets was 263.83% in 2021 against a maximum downside of 44.42% in 2021.
  • A 5-year view of Prepaid Assets shows it stood at $10.8 million in 2021, then skyrocketed by 65.59% to $17.9 million in 2022, then tumbled by 37.93% to $11.1 million in 2023, then crashed by 40.06% to $6.7 million in 2024, then dropped by 6.31% to $6.2 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Prepaid Assets are $6.2 million (Q4 2025), $8.7 million (Q3 2025), and $11.7 million (Q2 2025).